Cialis vs Sildenafil (Generic): Switching Between Them

How Tadalafil and Sildenafil Work

Both drugs block phosphodiesterase type-5 (PDE5), the enzyme that breaks down cyclic GMP in penile smooth muscle. Blocking PDE5 prolongs smooth-muscle relaxation, increases blood flow, and supports erection in response to sexual stimulation. Neither drug works without arousal.

The mechanism is shared, but the pharmacokinetics diverge significantly, which is what drives the clinical differences patients actually experience.

Receptor selectivity and tissue distribution

Sildenafil inhibits PDE5 with roughly equal potency for PDE6, the enzyme in retinal photoreceptors. That partial PDE6 effect explains the transient blue-tinge or photosensitivity some patients report at high doses [1]. Tadalafil is more selective for PDE5 over PDE6, but it does inhibit PDE11, found in skeletal muscle and testes. The clinical significance of PDE11 inhibition remains debated [2].

Half-life: the number that changes daily life

Sildenafil has a half-life of 3 to 5 hours [1]. Tadalafil's half-life is 17.5 hours, which is why a single 20 mg dose can still produce measurable plasma levels at 36 hours [2]. For patients who want a discrete, on-demand window, sildenafil's shorter duration means fewer cumulative hours of potential side effects. For couples who want spontaneous activity across a weekend, tadalafil's extended window is a practical advantage.

Efficacy Evidence for Erectile Dysfunction

The landmark 1998 Goldstein trial published in the New England Journal of Medicine (N=532) established sildenafil as the first oral PDE5 inhibitor proven effective for ED across etiologies including diabetes and spinal cord injury. At 100 mg, 69% of attempts resulted in successful intercourse, versus 22% on placebo (P<0.001) [1].

Tadalafil's key program, summarized by Brock et al. In the Journal of Urology (2002), demonstrated that tadalafil 20 mg produced successful intercourse in 75% of attempts at 24 hours post-dose and maintained efficacy at 36 hours, a window no sildenafil trial has matched [2].

Head-to-head data: what exists and what does not

No large randomized controlled trial has directly compared tadalafil to sildenafil in the same population on a primary efficacy endpoint. A 2011 Cochrane review of PDE5 inhibitors found all approved agents superior to placebo for ED, with no statistically significant differences in efficacy between drug classes when pooled across studies [3]. Patient preference, however, consistently favors tadalafil in crossover studies, largely because of its duration [4].

Diabetic and post-prostatectomy ED subgroups

In diabetic men, sildenafil improved erectile function scores by 7.5 points on the International Index of Erectile Function (IIEF) compared to placebo in the Goldstein trial subset [1]. Tadalafil 20 mg produced an IIEF improvement of 6.4 points in a dedicated diabetic ED trial (N=216) published in Diabetes Care [5]. Both effects are clinically meaningful; neither drug clearly dominates in this subgroup.

Post-radical prostatectomy ED is harder to treat with either agent. A meta-analysis in European Urology (N=1,865 across 14 trials) found response rates of 35 to 60% for PDE5 inhibitors post-prostatectomy, with nerve-sparing status being the strongest predictor of response, not drug choice [6].

Dosing: On-Demand vs. Daily

Sildenafil is dosed on-demand at 25 mg, 50 mg, or 100 mg, taken 30 to 60 minutes before anticipated activity. The FDA label recommends starting at 50 mg and adjusting based on response [7]. Taking it more than once in 24 hours is not recommended.

Tadalafil offers two distinct regimens. On-demand dosing starts at 10 mg (range 10 to 20 mg) taken at least 30 minutes before activity, with no more than one dose per 24 hours [8]. Daily dosing at 2.5 mg or 5 mg allows sexual activity at any point, eliminates the need to time medication, and, at 5 mg, carries an FDA approval for concurrent benign prostatic hyperplasia [8].

Why daily tadalafil changes the conversation

Men taking tadalafil 5 mg daily reach steady-state plasma concentrations within 5 days. A pooled analysis across three Phase III trials (N=1,054) showed daily tadalafil 5 mg improved IIEF-EF domain scores by 8.0 points from baseline versus 1.9 points for placebo (P<0.001) [9]. That continuous tissue exposure may also support endothelial health, though the clinical evidence for long-term vascular benefit remains preliminary [10].

Food and alcohol interactions

Sildenafil absorption drops by roughly 29% when taken with a high-fat meal, and time to peak concentration (Tmax) shifts from 1 hour to 2 hours [7]. A greasy dinner before a romantic evening can meaningfully blunt the drug's effect. Tadalafil pharmacokinetics are not significantly affected by food, which is a practical advantage for on-demand use [8].

Moderate alcohol (up to 3 units) does not significantly worsen hypotension with either drug, but alcohol above that threshold can amplify vasodilation, increasing dizziness and headache risk [11].

Side-Effect Profiles

Both drugs share a class-effect side-effect profile: headache, flushing, nasal congestion, and transient hypotension. The differences are meaningful at the margins.

Sildenafil-specific effects

Visual disturbances (blue-tinge or increased light sensitivity) affect roughly 3% of men at 100 mg because of sildenafil's partial PDE6 inhibition [1]. These are transient, lasting under 30 minutes in most cases, but they disqualify sildenafil for men with retinitis pigmentosa [7].

Tadalafil-specific effects

Back pain and myalgia occur in 3 to 6% of tadalafil users, particularly after the 20 mg dose, attributed to PDE11 inhibition in skeletal muscle [2]. Symptoms typically appear 12 to 24 hours after dosing and resolve within 48 hours without treatment. This side effect is rare with sildenafil [2].

Contraindications shared by both

Concurrent nitrate use is an absolute contraindication for both drugs. PDE5 inhibitors potentiate nitrate-induced hypotension and have caused deaths in men who combined them with nitroglycerin or isosorbide mononitrate [7, 8]. The FDA mandates a contraindication warning on both labels. Men on alpha-blockers require dose adjustment and timing separation; tadalafil's label specifies initiating tadalafil at 2.5 mg in men already on alpha-blocker therapy [8].

Severe hepatic impairment (Child-Pugh Class C) contraindicated tadalafil in the prescribing information and requires caution with sildenafil [7, 8]. Renal impairment below a creatinine clearance of 30 mL/min requires sildenafil dose reduction to 25 mg [7].

Switching Between Tadalafil and Sildenafil

Switching is safe and common. The clinical reason to switch is almost always one of four: inadequate efficacy, intolerable side effects, cost, or lifestyle preference.

The HealthRX clinical team uses the following decision framework when a patient requests a switch:

Switching FROM tadalafil TO sildenafil: Wait at least one tadalafil half-life (17.5 hours) after the last tadalafil dose before taking sildenafil. In practice, waiting 24 hours is a reasonable safety margin for most patients. Starting sildenafil at 50 mg is appropriate unless renal impairment or prior sensitivity to PDE5 inhibitors is documented.

Switching FROM sildenafil TO tadalafil: Because sildenafil's half-life is only 3 to 5 hours, a 24-hour gap after the last sildenafil dose is more than adequate before taking tadalafil. Tadalafil can be started at 10 mg on-demand or 5 mg daily; the on-demand 20 mg dose is reserved for patients who did not respond adequately to 10 mg.

Reasons patients switch from sildenafil to tadalafil

The most common patient-reported reason for switching to tadalafil in retrospective registry data is dissatisfaction with the narrow timing window of sildenafil, not lack of efficacy [4]. Men who describe feeling "performance pressure" because of the 4-hour window often report improved sexual confidence with tadalafil's 36-hour duration even before the first dose is taken, suggesting an expectation-mediated component [4].

Reasons patients switch from tadalafil to sildenafil

Back pain is the most commonly cited side effect prompting a switch from tadalafil to sildenafil, followed by cost [12]. Generic sildenafil 100 mg tablets are available in the United States for under $2 per pill through major pharmacy chains when purchased with a GoodRx-type coupon, compared to branded Cialis at $40, $80 per tablet. Generic tadalafil has narrowed this gap but remains more expensive on a per-dose basis in many markets.

What happens if you take both in the same 24-hour window

Taking both within a 24-hour window stacks their vasodilatory effects. Blood pressure drops are additive; one case series reported symptomatic hypotension in three patients who combined 100 mg sildenafil with 20 mg tadalafil taken 18 hours apart [11]. This combination is not recommended. No approved clinical indication requires concurrent use of two PDE5 inhibitors.

Cost and Access

Generic sildenafil entered the U.S. Market in 2017 following patent expiration, and prices dropped by over 90% within 24 months [12]. Generic tadalafil became widely available in the United States in 2018. As of 2024, average retail pricing per pill (without insurance) is approximately $1, $4 for generic sildenafil 100 mg and $3, $8 for generic tadalafil 20 mg, depending on pharmacy and location.

Both drugs require a prescription under current FDA regulations. Telehealth platforms, including HealthRX, can issue prescriptions following an asynchronous or synchronous clinical evaluation that meets standard-of-care requirements for ED diagnosis [13].

Insurance coverage differences

Most commercial insurance plans cover neither on-demand sildenafil nor on-demand tadalafil for ED, classifying both as lifestyle medications. Tadalafil 5 mg prescribed for BPH, however, is often covered under pharmacy benefits because BPH is coded as a medical condition (ICD-10 N40.x) rather than a sexual health indication [8, 14]. Men with both ED and BPH should confirm with their insurer whether the BPH indication changes their coverage.

Which Drug Is Right for You?

The right choice depends on lifestyle, comorbidities, and cost tolerance, not on one drug being categorically superior.

Choose tadalafil if:

• You want flexibility without timing pressure.
• You also have BPH symptoms (tadalafil 5 mg daily addresses both).
• High-fat meals are a regular part of your pre-activity routine.
• Visual side effects with sildenafil have been a prior problem.

Choose sildenafil if:

• Cost per dose is the primary concern.
• You prefer a shorter side-effect window.
• You take sildenafil on a predictable schedule and can plan timing.
• You have a history of significant myalgia with tadalafil.

Neither drug works in the absence of sexual stimulation, and neither addresses the underlying cause of ED. The American Urological Association guideline on ED (2018, amended 2024) recommends lifestyle modification, cardiovascular risk factor management, and shared decision-making about pharmacotherapy, noting that "PDE5 inhibitors are first-line therapy for most men with ED" [15].

Special Populations

Cardiovascular disease

The Princeton Consensus (Third Princeton Consensus Conference, 2012) stratified men with cardiovascular disease into low, intermediate, and high risk for sexual activity [16]. Low-risk patients (stable angina, controlled hypertension, NYHA Class I-II heart failure) can use either drug safely. High-risk patients, including those with unstable angina or who use short-acting nitrates, should not receive either drug until cardiovascular status is stabilized.

Older adults

Age alone does not contraindicate either drug, but older men metabolize both more slowly. The sildenafil FDA label recommends considering a starting dose of 25 mg in men over 65 because mean plasma concentrations are 40% higher in this group compared to men aged 18 to 45 [7]. Tadalafil's label does not mandate dose reduction based on age alone but advises clinical judgment [8].

Men with diabetes

Both drugs are effective in diabetic ED, though response rates are lower than in non-diabetic men. A 2018 meta-analysis in Diabetic Medicine (N=3,211 across 22 RCTs) found PDE5 inhibitors improved IIEF-EF scores by a pooled 5.2 points versus placebo in diabetic cohorts, with no statistically significant difference between individual agents [17].